Proxyfan

Proxyfan

SCHEMBL29462311

O=C(O)C(=O)O.c1ccc(COCCCc2cnc[nH]2)cc1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Proxyfan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.87
HRH4 Q9H3N8 3/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Proxyfan SCHEMBL15929504 0.93 HRH3 (1.00) HRH3HRH4
SCHEMBL4217229 0.76 HRH3 (0.58) HRH3HRH4
SCHEMBL18536735 0.76 HRH3 (0.57) HRH3HRH4
SCHEMBL2536900 0.75 HRH3 (0.93) HRH3HRH4
Proxyfan SCHEMBL15130144 0.74 HRH3 (0.48) HRH3HRH4
SCHEMBL224745 0.71 TAAR1 (1.00) HRH3HRH4
SCHEMBL6816189 0.70 LTA4H (0.58) HRH3HRH4
SCHEMBL194703 0.70 HRH3 (0.71) HRH3HRH4
SCHEMBL4069939 0.69 TDP1 (0.64) HRH3HRH4
SCHEMBL13851684 0.69 TBXAS1 (0.84) HRH3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2943564-B1 SL327 FOR USE IN SKIN REGENERATION INT STEM CELL CORPORATION (US) 2026-03-25 EP disclosed
US-20230035892-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER FLAGSHIP PIONEERING, INC. 2023-02-02 US disclosed
US-11383084-B2 Treatment of dermatological conditions via neuromodulation PALO ALTO INVESTORS (US) 2022-07-12 US disclosed
US-11274158-B2 Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-03-15 US disclosed